Swiss companies funneled $27 billion into the United States in just the first four months of 2026. The catalyst was a trade framework agreement announced on November 14, 2025, which slashed US tariffs on Swiss goods from 39% to 15%. In exchange, Swiss firms committed to at least $200 billion in US investments over five years, with a minimum of $67 billion earmarked for 2026 alone.
Pharma giants are writing the biggest checks
Roche announced a staggering $50 billion commitment for US-based manufacturing and research and development. Novartis is not far behind, pledging $23 billion across ten separate facilities in the United States.
Inside the tariff deal
The November 2025 agreement came amid escalating trade tensions initiated by the Trump administration, which had pushed Swiss tariffs to a punishing 39%. The resulting framework cut that rate to 15%. The deal also includes Liechtenstein, which shares a customs union with Switzerland. Further negotiations are ongoing to finalize a long-term trade accord.
What this means for investors
Thousands of jobs are expected to be created across multiple sectors, with pharma leading but not monopolizing the investment activity. The remaining $173 billion in the five-year commitment is not guaranteed. If talks stall or political winds shift, the 15% rate could revert, and companies that have not yet broken ground on their US facilities might reconsider.